Apolipoprotein E ε4 Allele Interacts with Sex and Cognitive Status to Influence All‐Cause and Cause‐Specific Mortality in U.S. Older Adults
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objectives: To confirm associations of apolipoprotein E ( A po E ) ε4 carrier status, sex, and time‐dependent cognitive status with mortality risk and to investigate these joint effects of these associations in a cohort of community‐dwelling U.S . adults. Design: Prospective cohort study. Setting: The Baltimore Longitudinal Study of Aging ( BLSA ). Participants: Of 3,047 BLSA participants aged 17 to 98 at first visit (60.1% male), 1,704 with complete ApoE genotype data were included, of whom 1,461 aged 50 and older with one or more visits were eligible. Measurements: Time to death from all, cardiovascular, and noncardiovascular causes. Results: Probability of survival was lower for A po E ε4 carriers, particularly those who were older. A Cox proportional hazards model for all‐cause mortality yielded a hazard ratio ( HR ) for A po E ε4 carrier versus noncarriers of 1.31 (95% confidence interval ( CI ) = 1.02–1.68). This association was also found for cardiovascular mortality. Time‐dependent all‐cause dementia ( HR = 1.73, 95% CI = 1.33–2.26) and mild cognitive impairment ( HR = 1.95, 95% CI = 1.42–2.67) increased all‐cause mortality risk, associations that were also detected for noncardiovascular mortality. When individuals were free of cognitive impairment, a dose‐response relationship with ε4 alleles was found for all‐cause mortality ( HR = 1.40, 95% CI = 0.94–2.07 for 1 ε4; HR = 2.61, 95% CI = 1.12–6.07 for 2 ε4). After onset of A lzheimer's disease ( AD ), carrying only one ε4 allele resulted in an approximately 77% greater all‐cause mortality risk than in noncarriers. ApoE ε4 carrier status increased all‐cause mortality risk in men and interacted with time‐dependent AD to increase the risk of this outcome (relative excess risk due to interaction = 2.15, 95% CI = 1.22–3.07). Conclusion: ApoE ε4 carrier status was found to increase all‐cause and cardiovascular mortality risks and interacted with sex and time‐dependent AD status to affect all‐cause mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“The apolipoprotein E (ApoE) e4 allele is the most robust genetic risk factor for late-onset Alzheimer’s disease (AD), conferring more than a three times greater risk.(1) In an ecological study, ApoE allele frequency differences explained 12% to 17% of country-level mortality variations and 1% to 2% of variation in old…”
BackgroundMorris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
Apolipoprotein E Polymorphism and Cardiovascular Disease: A HuGE Review
Eichner, J. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.6.487 · Cited by 796 · cited 1×
“Moreover, in large cohort studies and meta-analyses, carrying at least one e4 allele (ApoE e4 carrier) was related to greater risks of all-cause and cardiovascular mortality and higher incidence of coronary heart disease and stroke.(18,19) Other studies found no clear association between ApoE e4 carrier status and mor…”
BackgroundAssociation of apolipoprotein E genotypes with lipid levels and coronary risk
Bennet, A. M., Di Angelantonio, E., Ye, Z., Wensley, F., Dahlin, A., Ahlbom, A., Keavney, B., Collins, R., Wiman, B., de Faire, U., et al. (2007) · JAMA · doi:10.1001/jama.298.11.1300 · Cited by 794
Ingelsson, E., Schaefer, E. J., Contois, J. H., McNamara, J. R., Sullivan, L., Keyes, M. J., Pencina, M. J., Schoonmaker, C., Wilson, P. W. F., D’Agostino, R. B., et al. (2007) · JAMA · doi:10.1001/jama.298.7.776 · Cited by 608
Test for additive interaction in proportional hazards models
Li, R., & Chambless, L. (2007) · Annals of Epidemiology · doi:10.1016/j.annepidem.2006.10.009 · Cited by 548 · cited 1×
“RERI greater than 1 indicates synergism without needing to assume monotonicity of effects.(43,44)”
BackgroundInteraction as departure from additivity in case-control studies: a cautionary note
Skrondal, A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg113 · Cited by 180
Beydoun, M. A., Boueiz, A., Abougergi, M. S., Kitner-Triolo, M. H., Beydoun, H. A., Resnick, S. M., O'Brien, R., & Zonderman, A. B. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.017 · Cited by 139 · cited 1×
“A two-stage Heckman selection procedure was used in all Cox proportional hazards and competing risk models to address selection bias due to exclusion of participants without genetic data.(45,46)”
MethodSelf-citationCausal interactions in the proportional hazards model
VanderWeele, T. J. (2011) · Epidemiology · doi:10.1097/ede.0b013e31821db503 · Cited by 53 · cited 1×
“RERI greater than 1 indicates synergism without needing to assume monotonicity of effects.(43,44)”
Background
Cited by
Understanding the impact of sex and gender in Alzheimer’s disease: A call to action
Nebel, R. A., Aggarwal, N. T., Barnes, L. L., Gallagher, A., Goldstein, J. M., Kantarci, K., Mallampalli, M. P., Mormino, E. C., Scott, L., Yu, W. H., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.008 · Cited by 839
“[135] Beydoun MA, Beydoun HA, Kaufman JS, An Y, Resnick SM,”
BackgroundSex differences in cognitive impairment and Alzheimer’s disease
Li, R., & Singh, M. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.01.002 · Cited by 527
Huebbe, P., & Rimbach, G. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.06.002 · Cited by 195
Collaborators, G. 2. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12200 · Cited by 176
Maroon, J. C., Winkelman, R., Bost, J., Amos, A., Mathyssek, C., & Miele, V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117338 · Cited by 175
Mattsson, N., Groot, C., Jansen, W. J., Landau, S. M., Villemagne, V. L., Engelborghs, S., Mintun, M. M., Lleo, A., Molinuevo, J. L., Jagust, W. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.009 · Cited by 88
Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz402 · Cited by 86
Gamache, J., Yun, Y., & Chiba-Falek, O. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.045211 · Cited by 84
Rajan, K. B., Barnes, L. L., Wilson, R. S., McAninch, E. A., Weuve, J., Sighoko, D., & Evans, D. A. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15059 · Cited by 59
Metadata
- Authors
- Beydoun, M. A., Beydoun, H. A., Kaufman, J. S., An, Y., Resnick, S. M., O'Brien, R., Ferrucci, L., & Zonderman, A. B.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2013-03-21
- Volume
- 61
- Issue
- 4
- Pages
- 525-534
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W1966860490
- Cited by
- 38
- References
- 9
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.